H. Lundbeck A/S- (NASDAQ:HLUYY) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Friday. The firm currently has a $69.00 price objective on the stock. Zacks Investment Research‘s target price indicates a potential upside of 16.26% from the stock’s previous close.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Separately, Deutsche Bank AG lowered shares of H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a report on Friday, July 28th.

Shares of H. Lundbeck A/S- (NASDAQ HLUYY) traded down 0.40% during mid-day trading on Friday, reaching $59.35. 2,859 shares of the company’s stock were exchanged. The stock has a market cap of $11.72 billion and a PE ratio of 37.07. H. Lundbeck A/S- has a one year low of $31.00 and a one year high of $61.72. The company has a 50 day moving average price of $58.56 and a 200-day moving average price of $49.92.

COPYRIGHT VIOLATION WARNING: “H. Lundbeck A/S- (NASDAQ:HLUYY) Lifted to “Strong-Buy” at Zacks Investment Research” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/h-lundbeck-as-nasdaqhluyy-lifted-to-strong-buy-at-zacks-investment-research/1476079.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with Analyst Ratings Network's FREE daily email newsletter.